(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 June 2019 (13.06.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/112899 A3

(51) International Patent Classification:
C12N 5/074 (2010.01) *A61K 35/17* (2014.01)
C12N 5/078 (2010.01) *A61K 35/545* (2014.01)
C12N 5/0783 (2010.01) *A61K 39/395* (2006.01)
C07K 14/735 (2006.01)

(21) International Application Number:
PCT/US2018/063362

(22) International Filing Date:
30 November 2018 (30.11.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/596,659 08 December 2017 (08.12.2017) US
62/657,626 13 April 2018 (13.04.2018) US

(71) Applicant: **FATE THEREPEUTICS, INC.** [US/US]; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: **VALAMEHR, Bahram**; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US). **BJORDAHL, Ryan**; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US). **LEE, Tom, Tong**; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US). **GAIDAROVA, Svetlana**; 3535 General Atomics Court, Suite 200, San Diego, CA 92121 (US).

(74) Agent: **GAY, David, A.** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS




Figure 1

(57) Abstract: Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the used thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

WO 2019/112899 A3

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *with sequence listing part of description (Rule 5.2(a))*

(88) **Date of publication of the international search report:**
18 July 2019 (18.07.2019)